Dapagliflozin fails to get approval from FDA

Feb 9th 2012. The FDA said that more data is needed because of safety concerns linking dapagliflozin with breast cancer and bladder cancer. An FDA review of the data found a fourfold increased risk for breast cancer and fivefold increased risk for bladder cancer with dapagliflozin.

Posted in Drugs